Enhanced Access to Affordable Medicines Act of 2022
Summary
Enhanced Access to Affordable Medicines Act of 2022 This bill specifies that the Food and Drug Administration may approve generic drugs with different labels than the brand-name versions if, among other requirements, the brand-name drug is subject to an active patent or exclusivity period and a revised label for the brand-name drug is approved within 90 days (rather than 60 days) of the expiration of the patent or exclusivity period.
Bill status
in committee
1 of 4 stages cleared
Introduction
Mar 2022
Committee Review
Floor Vote
President
Introduced Mar 8, 2022
Last action Mar 9, 2022
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
3
Key actions
0
Committee
2
Mar 9, 2022
Committee
Referred to the Subcommittee on Health.
lower
Mar 8, 2022
Committee
Referred to the House Committee on Energy and Commerce.
lower
Mar 8, 2022
Introduced
Introduced in House
lower
1 primary · 1 co-sponsor
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 6973
Scope: US
Hi! I can help you understand HR 6973. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline